Home | Medical-Newswire.Com:
(EMAILWIRE.COM, March 21, 2012 ) New York, NY -- NovaBay Pharmaceuticals (NBY) released news this week that offers to broaden the scope and reach of the company's Aganocide compounds, which are being positioned as anti-infectives and could potentially replace modern day antibiotics as resistance to such treatment grows.
On Tuesday NovaBay announced a deal with Virbac Animal Health to bring its technology to the veterinary market. According to the agreement, NovaBay will receive an upfront payment - and some additional support for research and development - while Virbac will retain the option to license any of the Aganocide compounds that are successfully applied to treating veterinary indications.
The deal could provide NovaBay with a steady revenue stream in the future if Virbac exercises its licensing option. According to the Tuesday press release, if the option is exercised,
"NovaBay may receive additional payments, which include an exercise fee as well as development and pre-commercial milestones for a line of veterinary products. NovaBay will also receive royalties on sales of any successfully commercialized Aganocide products to arise from this agreement."
Few companies are going to become superpowers in the field of medicine on treating veterinary indications alone, but the deal brings some attention back to NovaBay and gives us another chance to consider this company's technology on the open market - should the pipeline products make it that far.
It also gives us the opportunity to determine whether or not the current market capitalization for NBY justifies that pipeline potential, which, in the opinion of this writer, the determination is "probably not."
First, let's revisit the problem of antibiotic resistance.
When introduced into society seventy years ago, antibiotics changed the shape of medicine, and provided what - at the time - was considered a huge leap forward in treating bacterial infections. Having been so widely-used since then, however, the infectious organisms against which the antibiotics are administered have grown increasingly resistant, and sometimes immune, to today's antibiotic treatments.
The Centers for Disease Control and Prevention considers the developing resistance to antibiotics as a "crisis", noting on its website that, "These drugs have been used so widely and for so long that the infectious organisms the antibiotics are designed to kill have adapted to them, making the drugs less effective. People infected with antimicrobial-resistant organisms are more likely to have longer, more expensive hospital stays, and may be more likely to die as a result of the infection."
Medical professionals themselves understand the growing risks associated with antibiotic resistance, as noted by Dr. Marc Siegel, associate professor of medicine and medical director of Doctor Radio at NYU Langone Medical Center, this week in an article published on FoxNews.com. Dr. Siegel also notes that Doctors continue to over prescribe these treatments, thereby strengthening the resistance of the surviving bacteria and creating new "super colonies" that will eventually be uncontrollable.
This dilemma has created a huge monetary burden on the global health care system and is possibly setting up a one-time "miracle cure" as irrelevant.
That's where NovaBay comes into the picture.
NovaBay has developed, through its proprietary Aganocide compounds, a pipeline of synthetic anti-infectives that are designed to mimic the body's own defenses against infection. Namely, these synthetic molecules, based on the Aganocide compound NVC-422, essentially act in the same manner and processes of a body's white blood cells and not as antibiotics, therefore significantly reducing the risk of a resistance being developed.
The potential of such a technology has market-moving implications, and under the circumstances, it's understandable why NBY could be tagged with an 'undervalued' label.
There are, however, a couple of reasons why investors may not yet have fully embraced the company and its technology. The first reason may be the most obvious one; that NovaBay still has nothing beyond Phase II, and therefore any investment in the company is highly speculative and risky at this point, which is a fair assessment.
That said, the best deals in biotech are the ones that are found early, when patience is needed as the trial results pan out. It's also worth noting, however, that he trend of staying away from speculative "Phase II" investments may be shifting.
Take Lpath, Inc. (LPTN), for example. Lpath also has a novel and potentially groundbreaking technology in the works, but Pfizer (PFI) has bucked the Phase II label of the company and jumped in with a very significant partnership.
CellDex Therapeutics (CLDX) is another one that has traded very highly during its Phase II stages, even when Pfizer decided to divorce itself from a partnership with the company.
In both cases, investors may have started to become clued in to how much market potential is contained within those respective pipelines and tossed the standard "wait until Phase III" strategy to the side. As investors with similar strategies in mind research NovaBay, the same potential for price appreciation exists; especially give the fact that NBY has a powerhouse partner of its own in Galderma SA, with whom NovaBay is developing a treatment for the highly-contagious skin condition, Impetigo.
Another reason why NovaBay may be missing the mark in terms of market cap right now, and this one may be more relevant than the last, is that an earlier clinical trial conducted with then-partner Alcon in the treatment of adenoviral conjunctivits - better known to the average Joe as "pink eye" - failed.
Shares slumped badly after that news hit the presses and have only barely recovered since.
On the flip side to the endpoint miss, however, which sent sent investors running for the doors, is that a further look at the data from the same trial did show that efficacy was demonstrated against Epidemic Keratoconjunctivitis (EKC), possibly the most contagious form of the infection, and which often threatens a victim's vision.
Based on that data, trials have continued, but the fact that the company has a failed trial under its belt most certainly deters some investors from jumping back in, at least until they see more results.
A Phase IIb trial for this indication is expected to begin within months, while another Phase II trial for the Impetigo condition is also slated for this year.
Results from 'Part A' from a trial testing NVC-422 as a treatment for urinary catheter blockage and encrustation (UCBE) have already rolled in, with results from 'Part B' also due within months.
The pending trial results provide some short term catalysts, but another catalyst due for this year could be the one that puts NovaBay on the map.
A commercial launch is planned for the short to mid term for NeutroPhase, NBY's first FDA-cleared product and a treatment for chronic wound in both hospital and personal care. A successful launch for NeutroPhase could alleviate many of the monetary concerns normally associated with a small company bringing its pipeline through trials, and just a couple of months ago the company announced its first strategic partner for NeutroPhase.
Having a product already on the market and bringing in revenue will go a long way to validating this small company in the eyes of potential investors, especially if the NeutroPhase commercial launch goes off without a hitch.
Based on the pending trial catalysts, the commercial launch of NeutroPhase, and most importantly, the potential of NVC-422 products on the open market as eventual substitutes for antibiotics, NBY may still be trading under the radar and could still be lightly valued, when all is considered.
By 2013 the NovaBay could have three Phase III trials ongoing with an FDA approved product on the market.
If that's the case, it's a fair bet to assume that the market cap will be significantly higher than thirty five million at that point.
For an example of how a shift from Phase II to Phase III can effect a market cap, one could look at Keryx BioPharmaceuticals (KERX). During the early to mid stages of Phase II, the KERX market cap was similar to NBY's now, but when Phase II trials were successful and Phase III came along?
Prices quickly quadrupled.
NovaBay's target market of anti-infective care is a multi-multi-billion dollar market annually, and NBY could quickly penetrate that market, as Doctors are currently looking for a way around antibiotic resistance.
As I've previously discussed, this company may be at the right place at the right time. For investors being in the right place at the right time means being "in" before any price run starts, and it's possible that NBY has a ways to move, should the pending catalysts turn out positive.
Disclosure: Long NBY.
For more information and commentary regading NBY, visit: http://vfcsstockhouse.com/blog/article/-novabay-may-be-in-the-right-place-at-the-right-time-with-an-answer-for-antibiotic-resistance
Contact VFC's Stock House: email@example.com
VFC's Stock House offers research-based investment information, insights and ideas on a variety of different companies in numerous sectors, with a focus on biotech stocks and healthcare.
For full reports on Celsius Holdings and other companies visit: http://vfcsstockhouse.com
Follow VFC's Stock House on Twitter: https://twitter.com/#!/VFCsStockHouse
'Like' VFC's Stock House on Facebook: http://www.facebook.com/pages/VFCs-Stock-House/143724412345213
For full disclaimer visit: http://vfcsstockhouse.com
VFC's Stock House
Health News Headlines - Yahoo News
Get the latest health news headlines from Yahoo News. Find breaking health news, including analysis and opinion on
top health stories.
Salmonella decline seen in food poisoning report
17 Apr 2014 at 1:26pm
NEW YORK (AP) ? The government's latest report card on food poisoning shows a dip in salmonella cases but an increase in illnesses from bacteria in raw shellfish. The report counts cases in only 10 states for some of the most common causes of foodborne illness, but is believed to be a good indicator of national food poisoning trends. Highlights from Thursday's report from the Centers for Disease Control and Prevention:
Study: Diabetic heart attacks and strokes falling
16 Apr 2014 at 5:56pm
NEW YORK (AP) ? In the midst of the diabetes epidemic, a glimmer of good news: Heart attacks, strokes and other complications from the disease are plummeting.
Obama: 8 million signed up for health care
17 Apr 2014 at 1:18pm
WASHINGTON (AP) ? Eight million people have signed up for health care through new insurance exchanges, President Barack Obama said Thursday, besting expectations and offering new hope to Democrats who are defending the law ahead of the midterm elections.
Free dermatology drug samples come at a cost
17 Apr 2014 at 1:52pm
By Andrew M. Seaman NEW YORK (Reuters Health) - Dermatologists tend to prescribe more expensive medications when they also give their patients drug samples, according to a new U.S. study. "If you're a patient who receives a sample, you may perceive that doctor is giving you better care because they gave you a gift," Dr. Alfred Lane told Reuters Health. "But that doctor may have increased your medical costs by giving you that sample." Lane is the study's senior author, from the Stanford University School of Medicine in Stanford, California. Addressing fellow dermatologists, he added, "You have to realize that these samples are making you write more expensive prescriptions." In an editorial accompanying the new study in JAMA Dermatology, Dr. Kenneth Katz and colleagues from Kaiser Permanente Northern California note that the drug industry in 2011 distributed $6.3 billion of samples.
FDA warns common uterine fibroid surgery can spread undetected cancer
17 Apr 2014 at 1:37pm
(Reuters) - The U.S. Food and Drug Administration warned that a common surgical procedure used to remove uterine fibroids could spread undetected uterine cancer. Data showed that the procedure, laparoscopic power morcellation, could significantly worsen a patient's chance of long-term survival, the regulator said. Uterine fibroids are benign tumors that usually pose no risk. However, certain women suffer from symptoms that include heavy or prolonged menstrual bleeding, pelvic pressure and frequent urination, which could warrant medical or surgical intervention.
Obama says health law is working, private insurance enrollment at 8 million
17 Apr 2014 at 1:20pm
President Barack Obama delivered a vigorous defense of his signature healthcare law on Thursday, saying private insurance enrollment under it has reached 8 million people and faulting Republicans for failing to agree with him that "this thing is working." The White House separately offered up statistics showing that 28 percent of those who signed up are between the ages of 18 and 34 years old. But we now know for a fact that repealing the Affordable Care Act would increase the deficit, raise premiums for millions of Americans and take insurance away from millions more," Obama told reporters at the White House.
Illinois investigates Herbalife as federal, state probes grow
17 Apr 2014 at 1:16pm
By Svea Herbst-Bayliss BOSTON (Reuters) - Illinois Attorney General Lisa Madigan's office said on Thursday it is investigating Herbalife Ltd, joining other state and federal probes of allegations that the weight loss and nutrition company is running a pyramid scheme. Madigan's office was urged to look into the company months ago by civil rights groups, which claimed it was a pyramid scheme targeting minorities. Hedge fund manager William Ackman was the first to call Herbalife a fraud and placed a $1 billion bet against the company in 2012. The company denies the allegations, and high-profile investors such as Carl Icahn, George Soros and Daniel Loeb have supported the company in the past by taking stakes.
Group Grieving May Help Families Through South Korea Ferry Disaster
17 Apr 2014 at 1:16pm
Grieving in Groups Beats Grieving Alone, Experts Say
Earnings lift S&P 500, Nasdaq; S&P's best week since July
17 Apr 2014 at 1:59pm
By Ryan Vlastelica NEW YORK (Reuters) - Stocks ended a holiday-shortened week with mostly modest gains on Thursday, though the S&P 500 notched its biggest weekly advance since July as Morgan Stanley and General Electric rallied after strong results. The two were the latest to post earnings that topped expectations, helping to lift the S&P 500 and the Nasdaq to their fourth straight daily advance. Tech bellwethers Google and IBM fell on disappointing figures and limited the broader market's gain. IBM's slide pushed the Dow into slightly negative territory at the close.
Merck's ragweed pollen allergy drug gets U.S. approval
17 Apr 2014 at 12:58pm
(Reuters) - The U.S. Food and Drug Administration has approved Merck & Co's pollen allergy drug Ragwitek. The tablet, which is administered by placing it under the tongue, is to treat the short ragweed pollen induced allergic rhinitis. Merck's Grastek will compete with Stallergenes SA's immunotherapy treatment for five types of grass pollen, which was approved by the FDA earlier this month.
Lowe's to pay $500,000 in EPA lead paint settlement
17 Apr 2014 at 12:17pm
By Julia Edwards WASHINGTON (Reuters) - Lowe's Home Centers, the No. 2 U.S. home improvement retail chain, has agreed to pay a $500,000 penalty for violating federal rules governing lead paint exposure, U.S. authorities said on Thursday. The Environmental Protection Agency and the Department of Justice said Lowe's had also agreed to implement a new compliance program at more than 1,700 stores nationwide. Lead exposure can cause a range of health problems, from behavioral disorders and learning disabilities to seizures and death. Lead-based paint was banned in the United States in 1978 but remains in many older homes and apartments.
Info may prompt seniors to taper off sleeping pills
17 Apr 2014 at 12:15pm
By Anne Harding NEW YORK (Reuters Health) - Older people are willing and able to get themselves off medications like sleeping pills once they're informed of the potential harms, according to a new Canadian study. "Even among patients who have been taking sleeping pills for 30 years, many of them in their 80s and 90s were able to get off the sleeping pills once they realized that these pills could cause falls, memory problems and car accidents," lead author Dr. Cara Tannenbaum of the University of Montreal told Reuters Health. While Valium, Xanax and similar medications, known as benzodiazepines, are not recommended for older adults given such risks, up to one-third of older adults still take them, usually to treat insomnia or anxiety, according to Tannenbaum and her colleagues. Doctors know about the dangers these drugs pose to their patients, the investigators write in JAMA Internal Medicine, but nearly half say they renew benzodiazepine prescriptions for their older patients anyhow, "citing patient dependence and benefit as justifications." Tannenbaum's team wanted to see whether educating older patients taking benzodiazepines about the risks would be an effective way to encourage some to stop using the drugs.
About 12 million U.S. outpatients misdiagnosed annually : study
17 Apr 2014 at 11:54am
Roughly 12 million adults who visit U.S. doctors' offices and other outpatient settings, or one in 20, are misdiagnosed every year, a new study has found, and half of those errors could lead to serious harm. The study by a team of Texas-based researchers attempted to estimate how often diagnostic errors occur in outpatient settings such as doctors' offices and clinics, as exact figures don't exist. Efforts to improve patient safety have largely focused on inpatient hospital care, including programs introduced by President Barack Obama's Affordable Care Act, even though most diagnoses are made in outpatient clinics, the study said. "It's important to outline the fact that this is a problem," said Dr. Hardeep Singh, the study's lead author and a patient safety researcher at Baylor College of Medicine in Houston and at the Michael E. DeBakey VA Medical Center, also in Houston.
UnitedHealth: New hepatitis C drug costs far more than forecast
17 Apr 2014 at 11:29am
UnitedHealth Group Inc, the largest U.S. health insurer, said it spent more than $100 million to cover a pricey new hepatitis C drug from Gilead Sciences Inc in its first three months on the market, an amount that was "multiple" times what it had expected. UnitedHealth is the first insurer to quantify its costs to cover patients using Gilead's new Sovaldi treatment, whose $84,000 price tag has spurred a national outcry over the rising costs of specialty medicines. UnitedHealth shares fell nearly 4 percent on Thursday and shares of rivals WellPoint Inc and Aetna Inc fell 3.8 percent and 3.4 percent, respectively, as investors weighed what their potential costs could be as well. Sovaldi has been shown to cure most patients of the liver-wasting virus with few side effects, but health officials, insurers and Medicaid directors are balking at the cost.
Reservoir to be flushed because of urinating teen
17 Apr 2014 at 11:22am
PORTLAND, Ore. (AP) ? The mix of 38 million gallons of treated water and one teen's urine has proven unacceptable to Portland officials who plan to flush away the whole lot ? the second time in less than three years the city has gone to such lengths to keep its water pure.